Skip to main content

27-04-2021 | Oncology | News | Article

News in brief

KEYNOTE-158 points to pembrolizumab potential in advanced mesothelioma

Shreeya Nanda

medwireNews: Pembrolizumab monotherapy can achieve responses lasting for more than a year in some patients with previously treated malignant pleural mesothelioma (MPM), suggest phase 2 trial data.

Of the 118 patients – all of whom had progressed on or were intolerant to standard therapy – in the MPM cohort of the KEYNOTE-158 study, 8% had a partial response to treatment with pembrolizumab 200 mg every 3 weeks.

Sixty percent of the responders were estimated to have a response lasting at least 12.0 months, and the median duration of response was 14.3 months (range, 4.0–33.9+ months).

The median progression-free and overall survival times were 2.1 and 10.0 months, respectively, report Timothy Yap (The University of Texas MD Anderson Cancer Center, Houston, USA) and co-investigators in The Lancet Respiratory Medicine.

They note that the PD-1 inhibitor had “manageable toxicity,” with grade 3–4 treatment-related adverse events (TRAEs) occurring in 16% of participants and serious TRAEs in 12%. The rate of discontinuation due to TRAEs was 11% and one death due to sleep apnea was considered related to study treatment.

The team concludes that these findings support the PD-1 and PD-L1 pathway “as a potential therapeutic target in some patients with previously treated mesothelioma, but biomarkers that can effectively identify such patients are yet to be elucidated.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Lancet Respir Med 2021; doi:10.1016/S2213-2600(20)30515-4

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage